Skip to content

Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma

Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00494923
Enrollment
2500
Registered
2007-07-02
Start date
1999-01-31
Completion date
2020-12-31
Last updated
2013-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma

Brief summary

The Erlangen Glaucoma Registry is a clinical registry for cross sectional and longitudinal observation of patients with open angle glaucoma (OAG) or glaucoma suspect, founded in 1991. The primary aim is the evaluation of diagnostic and prognostic validity of morphometrical, sensory and hemodynamical diagnostic procedures. No therapeutic studies are performed.

Detailed description

Purpose: Detection of onset and progression of structural and functional damage due to glaucoma. Determination of rate and amount of progressive change due to glaucoma. Characterisation of the relationship between structural and functional change over time. Evaluation of predictive factors for the development and progression of glaucoma.

Interventions

None listed

Sponsors

German Research Foundation
CollaboratorOTHER
University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Participants: * Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX or MDS, glaucoma suspects including ocular hypertension * Healthy volunteers (for cross sectional analysis only) Inclusion Criteria: * Open anterior chamber angle * Best corrected visual acuity 0.7 or better * Age between 18 and 65 years

Exclusion criteria

* Any eye disease other than glaucoma * Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus) * Myopic or hyperopic refractive error exceeding 8.0 diopters

Design outcomes

Primary

MeasureTime frame
Time to Disease Progressionup to 20 years

Countries

Germany

Contacts

Primary ContactAnselm G Juenemann, Prof.
anselm.juenemann@uk-erlangen.de**49-9131-8533001

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026